Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.40 |
| ▸ | HTT | P42858 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116369 | 1.00 | LMNA (0.40) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL5624295 | 0.88 | MAPT (0.41) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL5624297 | 0.88 | MAPT (0.41) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL7087692 | 0.87 | PDPK1 (0.36) | SMN1; SMN2MEN1KMT2ATSHRNPSR1 | |
| SCHEMBL7087687 | 0.87 | PDPK1 (0.36) | SMN1; SMN2MEN1KMT2ATSHRNPSR1 | |
| SCHEMBL436205 | 0.87 | KMT2A (0.35) | LMNASMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL436206 | 0.87 | KMT2A (0.35) | LMNASMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL7494041 | 0.86 | BRD4 (0.45) | HTTSMN1; SMN2MAPK1MAPTMEN1 | |
| SCHEMBL7494033 | 0.86 | BRD4 (0.45) | HTTSMN1; SMN2MAPK1MAPTMEN1 | |
| SCHEMBL6318774 | 0.85 | L3MBTL1 (0.38) | LMNAHTTSMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2281561-A2 | Use of LCK inhibitors for treatment of immunologic diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-02-09 | — | — | EP | claimed |
| US-20090306104-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| US-20090087405-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-02 | — | — | US | claimed |
| EP-1530466-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | Boehringer Ingelheim Pharma KG (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20040204458-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-14 | — | — | US | claimed |
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| WO-2004017948-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | claimed |
| US-6638965-B2 | Antitumor agents | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-28 | — | — | US | claimed |
| EP-1341760-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | claimed |
| WO-2002036564-A1 | SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-05-10 | — | — | WO | claimed |
| US-7989474-B2 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2011-08-02 | — | — | US | disclosed |
| EP-2281561-A2 | Use of LCK inhibitors for treatment of immunologic diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-02-09 | — | — | EP | disclosed |
| US-20090306104-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090087405-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-02 | — | — | US | disclosed |
| WO-2004017948-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | disclosed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | disclosed |
| US-6638965-B2 | Antitumor agents | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | LMNA 1494/4885HTT 3721/4885SMN1; SMN2 3748/4885 |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | LMNA 1494/4885HTT 3721/4885SMN1; SMN2 3748/4885 |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, CSNK1A1, MKI67 | LMNA 773/4885HTT 3609/4885SMN1; SMN2 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.